Figure 1From: Detection of in vivo atherosclerotic plaque progression with a fibrin-targeted MR contrast agentRepresentative images from (A) pre- EP-2104R in 12 week HFD ApoE -/- mice, and 1.5 - 2 hours after i.v. administration of 10 μmol/kg EP-2104R in (B) week HFD Apoe -/- mice and (C) 12 week HFD ApoE -/- mice.Back to article page